Agents Inside the Perimeter: Phylo and Chugai Deploy Biomni Lab Across Discovery Workflows

Phylo and Chugai Pharmaceutical announced on August 4, 2026 that Chugai will deploy Biomni Lab — Phylo's agentic AI platform for biomedical research — across drug discovery workflows covering single-cell analysis, human genetics, disease biology, and target evaluation.

Integrated Biology Environment

Biomni Lab connects more than 300 databases, software systems, and analytical tools into a single workspace. Agents run on Chugai's proprietary research data inside its security perimeter.

Sohei Oyama, head of Chugai's biological technology department, said scientists need tools "designed for the unique challenges of drug discovery research."

From open source to enterprise

Chugai scientists were among Biomni's earliest users after the open-source release. Kexin Huang, Phylo CEO, said the partnership demonstrates "how agentic AI can accelerate breakthrough discovery."

What this is not

The announcement describes platform deployment intent, not published clinical outcomes.

### Sources

• Phylo — Phylo and Chugai partner to advance AI agents in drug discovery (August 4, 2026)
• PR Newswire — Phylo and Chugai partner to advance AI agents in drug discovery (August 4, 2026)
• Unite.AI — Chugai Deploys Phylo's Biomni Lab AI Agents Across Drug Discovery (August 2026)